Clinical safety studies involving approximately 900 participants showed no clinically significant hormonal changes with AOD-9604, consistent with its peripheral, fat-tissue-specific mechanism of action
The following populations have no published exposure data and would generally be excluded from research-context use: - People who are pregnant, trying to become pregnant, or breastfeeding
The clinical trials that led to FDA approval demonstrated consistent reductions in visceral adipose tissue, measured by imaging
The complex will provide a rapid boost of energy for individuals feeling run down or fatigued
In most other countries the maximum time between injections is two months
This dosage is often given daily for a week, then weekly for a month, and monthly for maintenance, based on the deficiencys severity